JP7347899B2 - Ｃｄ８結合物質 - Google Patents

Ｃｄ８結合物質 Download PDF

Info

Publication number
JP7347899B2
JP7347899B2 JP2020507586A JP2020507586A JP7347899B2 JP 7347899 B2 JP7347899 B2 JP 7347899B2 JP 2020507586 A JP2020507586 A JP 2020507586A JP 2020507586 A JP2020507586 A JP 2020507586A JP 7347899 B2 JP7347899 B2 JP 7347899B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cells
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020507586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530299A5 (enExample
JP2020530299A (ja
Inventor
クレイ、ニコライ
タベルニエ、ジャン
ザベアウ、レナルト
デプラ、エリク
Original Assignee
オリオンズ バイオサイエンス インコーポレイテッド
オリオンズ バイオサイエンス ビーブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリオンズ バイオサイエンス インコーポレイテッド, オリオンズ バイオサイエンス ビーブイ filed Critical オリオンズ バイオサイエンス インコーポレイテッド
Publication of JP2020530299A publication Critical patent/JP2020530299A/ja
Publication of JP2020530299A5 publication Critical patent/JP2020530299A5/ja
Priority to JP2023103640A priority Critical patent/JP2023112153A/ja
Application granted granted Critical
Publication of JP7347899B2 publication Critical patent/JP7347899B2/ja
Priority to JP2025076447A priority patent/JP2025109736A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020507586A 2017-08-09 2018-08-08 Ｃｄ８結合物質 Active JP7347899B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023103640A JP2023112153A (ja) 2017-08-09 2023-06-23 Ｃｄ８結合物質
JP2025076447A JP2025109736A (ja) 2017-08-09 2025-05-01 Ｃｄ８結合物質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762542920P 2017-08-09 2017-08-09
US62/542,920 2017-08-09
PCT/US2018/045741 WO2019032661A1 (en) 2017-08-09 2018-08-08 CD8 LIAISON AGENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103640A Division JP2023112153A (ja) 2017-08-09 2023-06-23 Ｃｄ８結合物質

Publications (3)

Publication Number Publication Date
JP2020530299A JP2020530299A (ja) 2020-10-22
JP2020530299A5 JP2020530299A5 (enExample) 2021-09-16
JP7347899B2 true JP7347899B2 (ja) 2023-09-20

Family

ID=65272669

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020507586A Active JP7347899B2 (ja) 2017-08-09 2018-08-08 Ｃｄ８結合物質
JP2023103640A Pending JP2023112153A (ja) 2017-08-09 2023-06-23 Ｃｄ８結合物質
JP2025076447A Pending JP2025109736A (ja) 2017-08-09 2025-05-01 Ｃｄ８結合物質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023103640A Pending JP2023112153A (ja) 2017-08-09 2023-06-23 Ｃｄ８結合物質
JP2025076447A Pending JP2025109736A (ja) 2017-08-09 2025-05-01 Ｃｄ８結合物質

Country Status (6)

Country Link
US (3) US11566072B2 (enExample)
EP (1) EP3665201A4 (enExample)
JP (3) JP7347899B2 (enExample)
CN (1) CN111511763B (enExample)
CA (1) CA3069930A1 (enExample)
WO (1) WO2019032661A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
EP3455245A2 (en) * 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
EP3665201A4 (en) * 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
CN113840833B (zh) 2019-03-28 2025-06-17 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
TW202519557A (zh) * 2019-09-04 2025-05-16 美商建南德克公司 Cd8 結合劑及其用途
AU2020361683A1 (en) * 2019-10-11 2022-05-19 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CA3185087A1 (en) * 2020-07-07 2022-01-13 Nikolai Kley Immunostimulatory adjuvants
EP4186925A4 (en) * 2020-07-21 2025-01-22 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. CD8-BINDING POLYPEPTIDE AND USE THEREOF
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
AU2022218137A1 (en) * 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
CN114230665B (zh) * 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
WO2023076876A1 (en) * 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
JP2025508298A (ja) * 2021-12-29 2025-03-26 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー シングルドメイン高親和性抗体及びその使用方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
CN115927342B (zh) * 2022-07-08 2025-09-23 新疆医科大学 特异识别CD8α分子的高亲和力核酸适配体
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
US20260102527A1 (en) * 2023-01-27 2026-04-16 Vrije Universiteit Brussel CD8b-BINDING POLYPEPTIDES
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526332A (ja) 1999-03-12 2003-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄ８＋細胞を単離する方法、並びに関連するハイブリドーマ細胞、抗体及びポリペプチド
WO2007110231A2 (en) 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
JP2015500796A (ja) 2011-10-28 2015-01-08 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
JP2015511219A (ja) 2012-01-20 2015-04-16 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 標的変異体αヘリックスバンドルサイトカイン
JP2016520514A (ja) 2013-03-13 2016-07-14 イマジナブ、 インコーポレイテッド Ｃｄ８に対する抗原結合性構築物
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489116B1 (en) 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2010030671A1 (en) 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
EP4450523A3 (en) * 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
RU2577299C2 (ru) 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
WO2013053008A2 (en) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molecules which bind clec9a
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014088890A1 (en) * 2012-12-03 2014-06-12 The Regents Of The University Of California Non-competitive immunoassays to detect small molecules using nanopeptamers
WO2014122183A1 (en) 2013-02-05 2014-08-14 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
CA2918518C (en) 2013-07-19 2022-08-16 Universiteit Gent Targeted modified il-1 family members
MX370565B (es) 2013-07-19 2019-12-17 Vib Vzw Miembros de la familia tnf modificados dirigidos.
US9732135B2 (en) 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
CN110114368B (zh) * 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3665201A4 (en) * 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526332A (ja) 1999-03-12 2003-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄ８＋細胞を単離する方法、並びに関連するハイブリドーマ細胞、抗体及びポリペプチド
WO2007110231A2 (en) 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
JP2015500796A (ja) 2011-10-28 2015-01-08 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
JP2015511219A (ja) 2012-01-20 2015-04-16 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 標的変異体αヘリックスバンドルサイトカイン
JP2016520514A (ja) 2013-03-13 2016-07-14 イマジナブ、 インコーポレイテッド Ｃｄ８に対する抗原結合性構築物
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof

Also Published As

Publication number Publication date
CN111511763B (zh) 2024-05-31
US20260125473A1 (en) 2026-05-07
JP2023112153A (ja) 2023-08-10
US11566072B2 (en) 2023-01-31
EP3665201A4 (en) 2021-06-02
US20230142099A1 (en) 2023-05-11
EP3665201A1 (en) 2020-06-17
WO2019032661A1 (en) 2019-02-14
CN111511763A (zh) 2020-08-07
CA3069930A1 (en) 2019-02-14
US12448447B2 (en) 2025-10-21
JP2020530299A (ja) 2020-10-22
JP2025109736A (ja) 2025-07-25
US20200231674A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
US12448447B2 (en) CD8 binding agents
US12351633B2 (en) PD-1 and PD-L1 binding agents
JP7746499B2 (ja) Ｃｌｅｃ９ａ結合物質およびその使用
JP6991979B2 (ja) Ｃｄ８結合物質
JP2024026876A (ja) 線維芽細胞結合物質およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230904

R150 Certificate of patent or registration of utility model

Ref document number: 7347899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150